MCI Health Networks (MCI) is a Deep Tech, B2B2C SaaS, digital healthcare and Life Sciences innovator focused upon safe, sustainable, non-starvation, non-GLP1 agonist, medical weight loss, validated cost savings, metadata, and value-based care analytics as the world’s only known patent pending, AI-enabled, self-contained, automated, massively scalable solution for for virtual Adiposity Based Chronic Disease remission (ABCD) and Type 2 Diabetes (T2D) remission.
Global Problem
Hundreds of millions of people globally yo-yo back and forth between weight loss starvation and expensive, unsafe GLP1- agonists due to unhealthy habits stored in their subconscious brain.
Cost: Outrageous! (CMS spends 1/4-1/3 annually on diabetes alone!)
Neuroplasticity – The brain’s ability to respond, modify, change and solidify learned cognitive information by creating structural and functional pathways (Wikipedia).
With the brain’s Neuroplasticity, MCI has the patent pending solution for sustaining medical weight loss by unlearning unhealthy habits!!!
“It’s how we grow as people”. (Grace Tworek, PsyD)
“CBT”: Cognitive Behavioral Therapy. The GOLD STANDARD for Psychology and Psychiatry since the late 1960’s. (Behavior, Lifestyle, Diet)
“Daily Therapy ©” 60 automated CBT podcasts & quizzes by personal virtual assistant.
Patent pending, AI-enabled CBT, personal clinical results, intuitive personal algorithm messages and reminders by Personal Virtual Assistant (PVA) for Neuroplasticity for safe, rapid, sustainable medical weight loss.
• 93N T2D
• 73.1% (19/26N) T2D Remission x 9.79 months
• 64% lost 10% or more weight
• 800 cal/d high protein ketogenic diet
Expand, FULLY Automate, and Massively scale to complete the remaining 50% of the Product Market Fit (PMF) to decrease staff burden and costs, and improve Quality of Care.
• Launch B2B2C sales $4664pp Y1 + Y2 $2,000 maintenance
• T2D cost = $20,000 pppy (CDC 2025)
• MCI estimated cost savings: $15,000
Samuel is a retired heart surgeon. He was an international Principal Investigator for FDA Phase III Trials for ATS Medical, Inc. (ATSI-Nasdaq). He founded University Medical Clinics Inc., a network of primary care clinics contracting with Medicare and HMOs. Samuel co-authored the company’s Daily Therapy© software and was the Investigator for the company’s virtual Phase I/II T2DM remission trials. He’s a graduate of Chicago Medical School.
John Hablak is an experienced and highly effective entrepreneur, having graduated University Colorado in operations management. In 2017 he co-founded and successfully operates the then largest medical marijuana clinic in South Florida. He has since separately acquired a major primary care medical clinic.
Jason is a US Navy veteran and liaison with the web technology and operations teams. He was a network development executive in the HMO industry and formerly COO of University Medical Clinics, Inc. He co-authored the company’s Daily Therapy© software and AI-based personal algorithms. Jason and Samuel co-designed the company’s patent-pending ecosystem.
Nick is acting COO and formerly Southeast US and Northern Caribbean Operations Director for St. Jude Medical and Medtronic. He was charged with contracting and purchasing with some of the country’s largest hospital systems. He is co-founder of Chelexa BioSciences, a patented technology to prevent MRSA, licensed to Hoth Therapeutics (NASDAQ). Nick is a Vietnam veteran serving as a Captain in the US Marine Corp.
For information, please contact Samuel Sadow, CEO, ssadow@mcihealth.com or 772 233-8183.